PURPOSE: The aim of the study was to report and discuss the preliminary data obtained in a homogeneous series of 50 patients affected by multiple myeloma treated with bisphosphonates. METHODS: Patients were followed for a minimum of 1 year. Main orthopaedic data were recorded. Visual Analogue Score and QLQ-C30 and MY 20 were used to assess the quality of life. RESULTS: Statistical analysis showed less lytic lesions in the group with zoledronate therapy and stable primary disease compared with a greater number of lesions in the non-treated group. Results regarding VAS score and QLQ-C30 and MY were statistically better in the first group than in the second. CONCLUSIONS: Our results confirm the efficacy of zoledronate in ensuring an acceptable quality of life restraining the aggressiveness of the myeloma on bone tissue, especially in spine although further prospective studies have to be conducted to determine its correct use in myeloma patients.
PURPOSE: The aim of the study was to report and discuss the preliminary data obtained in a homogeneous series of 50 patients affected by multiple myeloma treated with bisphosphonates. METHODS:Patients were followed for a minimum of 1 year. Main orthopaedic data were recorded. Visual Analogue Score and QLQ-C30 and MY 20 were used to assess the quality of life. RESULTS: Statistical analysis showed less lytic lesions in the group with zoledronate therapy and stable primary disease compared with a greater number of lesions in the non-treated group. Results regarding VAS score and QLQ-C30 and MY were statistically better in the first group than in the second. CONCLUSIONS: Our results confirm the efficacy of zoledronate in ensuring an acceptable quality of life restraining the aggressiveness of the myeloma on bone tissue, especially in spine although further prospective studies have to be conducted to determine its correct use in myelomapatients.
Authors: Sharon Gordon; Miep H Helfrich; Hamdi I A Sati; Michael Greaves; Stuart H Ralston; Dominic J Culligan; Richard L Soutar; Michael J Rogers Journal: Br J Haematol Date: 2002-11 Impact factor: 6.998
Authors: S Derenne; M Amiot; S Barillé; M Collette; N Robillard; P Berthaud; J L Harousseau; R Bataille Journal: J Bone Miner Res Date: 1999-12 Impact factor: 6.741
Authors: Peter I Croucher; Raeve De Hendrik; Mark J Perry; Anja Hijzen; Claire M Shipman; Jennifer Lippitt; Jonathan Green; Eric Van Marck; Ben Van Camp; Karin Vanderkerken Journal: J Bone Miner Res Date: 2003-03 Impact factor: 6.741
Authors: James R Berenson; Bruce E Hillner; Robert A Kyle; Ken Anderson; Allan Lipton; Gary C Yee; J Sybil Biermann Journal: J Clin Oncol Date: 2002-09-01 Impact factor: 44.544
Authors: B Djulbegovic; K Wheatley; J Ross; O Clark; G Bos; H Goldschmidt; F Cremer; M Alsina; A Glasmacher Journal: Cochrane Database Syst Rev Date: 2002
Authors: E Terpos; O Sezer; P I Croucher; R García-Sanz; M Boccadoro; J San Miguel; J Ashcroft; J Bladé; M Cavo; M Delforge; M-A Dimopoulos; T Facon; M Macro; A Waage; P Sonneveld Journal: Ann Oncol Date: 2009-05-22 Impact factor: 32.976
Authors: Georg Bier; Christopher Kloth; Christoph Schabel; Malte Bongers; Konstantin Nikolaou; Marius Horger Journal: Skeletal Radiol Date: 2016-01 Impact factor: 2.199
Authors: Juan Wu; Wei Zheng; Yan Tan; Xiao-Yuan Hu; Quan Huang; Kai-Hua Fan; Jie Ma; Wen-Jing Xiao; Jian-Dong Ren; Jun Hou; Jian-Ru Xiao Journal: Biomed Res Int Date: 2015-01-22 Impact factor: 3.411